List of Excipients in Branded Drug AFEDITAB

« Back to Dashboard

Generic Drugs Containing AFEDITAB

Company	Ingredient	NDC	Excipient
Aphena Pharma Solutions - Tennessee LLC	nifedipine	43353-782	AMMONIA
Aphena Pharma Solutions - Tennessee LLC	nifedipine	43353-782	BUTYL ALCOHOL
Aphena Pharma Solutions - Tennessee LLC	nifedipine	43353-782	FERRIC OXIDE RED
Aphena Pharma Solutions - Tennessee LLC	nifedipine	43353-782	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in AFEDITAB?

# Of NDCs	Excipient
2	AMMONIA
2	BUTYL ALCOHOL
1	CELLULOSE, MICROCRYSTALLINE
2	FERRIC OXIDE RED

AFEDITAB Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

AFEDITAB CR is a controlled-release nifedipine tablet for hypertension. Its commercial value is tied less to the active ingredient, which is widely genericized, and more to release-control performance, manufacturing consistency, tablet robustness, photostability, and differentiated dosing formats. The strongest opportunities are lower-cost supply, improved once-daily delivery, adherence-oriented packaging, and lifecycle products that reduce formulation or administration burdens.

What is AFEDITAB and how is it regulated?

AFEDITAB CR contains nifedipine, a dihydropyridine calcium-channel blocker. The product is an extended-release oral tablet administered once daily for hypertension. Nifedipine immediate-release products have different safety and dosing considerations and should not be treated as interchangeable with controlled-release formulations.[1]

Attribute	AFEDITAB CR
Active ingredient	Nifedipine
Dosage form	Extended-release tablet
Listed strengths	30 mg and 60 mg
Primary use	Hypertension
Regulatory pathway	Abbreviated New Drug Application or legacy generic approval pathway, depending on product holder and application
Administration	Once daily, swallowed whole
Core technical challenge	Maintaining a predictable nifedipine release profile over the dosing interval
Commercial category	Mature generic cardiovascular product

Nifedipine has low aqueous solubility and is sensitive to environmental exposure, including light. These properties make excipient selection and process control material to product performance rather than simple cost variables.[2]

What excipients are used in AFEDITAB CR?

Public product labeling identifies the qualitative excipient system but generally does not disclose the precise quantity of each inactive ingredient. The AFEDITAB CR formulation is understood to use a controlled-release matrix or release-controlling tablet architecture supported by conventional tablet excipients.

Potential excipient functions include:

Formulation function	Likely excipient category	Commercial purpose
Release control	Hydrophilic polymer, such as hypromellose	Regulates water ingress, gel formation, and nifedipine diffusion
Dilution and tablet mass	Microcrystalline cellulose, lactose, or another filler	Provides compressibility and consistent tablet weight
Lubrication	Magnesium stearate or equivalent	Reduces tooling friction and ejection force
Flow improvement	Colloidal silicon dioxide	Improves powder flow and blend uniformity
Film coating	Polymer, plasticizer, pigment, and opacifier	Protects the tablet, improves appearance, and supports light protection
Moisture and light protection	Coating system and protective packaging	Limits degradation and preserves dissolution performance

The critical excipient is the release-controlling polymer. Changes in polymer viscosity grade, particle size, substitution level, hydration behavior, or supplier can alter dissolution. A nominally equivalent formulation may fail comparative dissolution if the polymer network forms too quickly, erodes too rapidly, or changes permeability.

How should an AFEDITAB excipient strategy be designed?

A commercially viable strategy should divide excipients into three groups: performance-critical, quality-critical, and readily substitutable.

Performance-critical excipients

The release-controlling polymer should receive the highest level of supply-chain and change-control protection. The formulation team should control:

• Polymer viscosity range
• Degree of substitution
• Particle-size distribution
• Moisture content
• Bulk density
• Hydration and gel-strength behavior
• Supplier manufacturing site
• Compendial status and residual-solvent profile

For nifedipine ER tablets, polymer substitution should be supported by comparative dissolution across multiple pH conditions and, where relevant, alcohol-containing media. The objective is not merely to match a single dissolution point. The target is a robust release profile across the full specification range.

Quality-critical excipients

Coating materials, pigments, glidants, and lubricants can affect stability, blend uniformity, tablet hardness, friability, and appearance. Magnesium stearate is a common example. Excessive lubrication can reduce tablet wettability and slow dissolution; inadequate lubrication can produce sticking, capping, and weight variation.

The coating system should provide:

• Adequate light attenuation
• Low moisture permeability
• Resistance to abrasion during shipping
• Consistent weight gain
• Acceptable swallowing characteristics
• Compatibility with the release matrix

Readily substitutable excipients

Some fillers and processing aids can be dual sourced with lower regulatory and technical risk if the product maintains its critical quality attributes. Supplier changes should still be assessed under the applicable post-approval change framework. In a mature generic product, cost reduction is most practical when it does not alter the release-controlling architecture.

What formulation risks affect AFEDITAB CR?

Dose dumping

The principal technical risk is an unexpectedly rapid release of nifedipine. The risk can arise from polymer variability, tablet damage, excessive compression-force changes, coating defects, or interactions with alcohol-containing media. Extended-release products require dissolution testing designed to detect accelerated release rather than relying only on standard quality-control time points.[3]

Food effects

Food can alter gastrointestinal transit, fluid availability, and drug dissolution. A robust formulation should minimize clinically meaningful differences between fasted and fed conditions. Food-effect data are particularly relevant if a reformulated product is intended to support broader labeling or a differentiated patient-use claim.

Light sensitivity

Nifedipine is photosensitive. Light-protective film coatings, opaque containers, foil-based blister systems, and controlled warehouse exposure can reduce degradation risk. A lower-cost package that weakens light protection may create stability or complaint risk even if the tablet formulation remains unchanged.

Tablet integrity

AFEDITAB CR must generally be swallowed whole. Scoring, crushing, splitting, or chewing can change the release rate. Commercial opportunities that add a score line or smaller tablet must be supported by release testing and a clear administration strategy. A smaller tablet is attractive for dysphagia and adherence, but it can also increase surface area and alter release kinetics.

What formulation patents protect AFEDITAB-type products?

The active ingredient nifedipine is long off-patent. Any meaningful intellectual-property position would more likely arise from:

• Extended-release matrix composition
• Specific polymer ratios
• Coating architecture
• Particle-size or solid-state control
• Manufacturing parameters
• Packaging that protects against light or moisture
• Fixed-dose combinations
• New dosage forms or administration routes

The strongest historical protection for branded nifedipine extended-release products has generally centered on dosage-form technology rather than the molecule itself. For a mature AFEDITAB-type product, formulation patents must be evaluated by claim scope, expiration, terminal disclaimers, prosecution history, and whether the claims cover the commercial product rather than a broader but unsupported formulation concept.

A new excipient combination is not automatically patentable. Patent value is higher when the formulation produces a measurable technical effect, such as:

• Reduced food sensitivity
• Narrower dissolution variability
• Improved photostability
• Lower tablet size at the same dose
• Reduced polymer loading
• Improved manufacturability
• Lower incidence of dose dumping under stress conditions

What is the Orange Book status of AFEDITAB?

FDA Orange Book analysis should distinguish the reference-listed product from approved generic products and should separately review active patent and exclusivity entries. For a mature nifedipine extended-release product, the principal regulatory barrier is usually abbreviated-application approval and demonstration of therapeutic equivalence rather than new chemical-entity exclusivity.

Key Orange Book questions include:

1. Is AFEDITAB CR listed as the reference-listed drug or as an approved generic?
2. Are any unexpired formulation or method-of-use patents listed?
3. Are the 30 mg and 60 mg strengths separately listed?
4. Does the product have a therapeutic-equivalence code that supports substitution?
5. Are any exclusivity periods still active?
6. Has a Paragraph IV certification been filed against listed patents?

FDA's Orange Book identifies approved drug products, therapeutic-equivalence evaluations, patent information, and exclusivity data.[4] Because listings can change, the commercial assessment should be based on the current FDA database entry rather than an historical label or patent record.

When does AFEDITAB lose exclusivity?

Nifedipine itself has no meaningful new-molecule exclusivity remaining. Any remaining exclusivity risk would relate to a product-specific formulation, method-of-use, or regulatory designation. For an established extended-release generic, the practical launch barrier is more likely to be:

• ANDA review timing
• Bioequivalence or comparative dissolution failure
• Manufacturing-site readiness
• Product-specific guidance
• Patent certification risk
• Commercial ability to obtain pharmacy and wholesaler access

A Paragraph IV challenge would matter only if an unexpired listed patent covers the reference product or its protected use. A generic applicant could also pursue a Paragraph III certification for delayed launch or a Paragraph IV certification for invalidity, unenforceability, or non-infringement under the Hatch-Waxman framework.[5]

Which companies are challenging AFEDITAB or competing in nifedipine ER?

Nifedipine ER is a competitive generic market with products associated with multiple manufacturers and labelers. Competition can arise from:

• Generic versions of Procardia XL
• Generic versions of Adalat CC
• Other nifedipine ER tablets
• Authorized generics
• Therapeutic alternatives such as amlodipine, felodipine, and nicardipine
• Combination antihypertensive products

The relevant competitor is not only another nifedipine tablet. Amlodipine is a major commercial substitute because it is once daily, widely available, and commonly used in hypertension treatment. Nifedipine ER can compete through pregnancy-related prescribing considerations, specific patient response, formulary position, and price.

Competitive product	Commercial comparison
AFEDITAB CR	Nifedipine ER; opportunity depends on manufacturing cost, supply reliability, and formulary access
Procardia XL generic equivalents	Direct formulation and substitution competitors
Adalat CC generic equivalents	Compete in the same active-ingredient class but may use different release technologies
Amlodipine	Strong therapeutic substitute with broad generic availability
Felodipine ER	Smaller therapeutic competitor with extended-release positioning

What commercial opportunities exist for AFEDITAB excipients?

Lower-cost polymer sourcing

The clearest opportunity is dual sourcing of the release-controlling polymer. A second qualified supplier can reduce dependency on a single vendor and improve negotiating leverage. The change requires comparative material characterization and dissolution evidence.

Smaller, easier-to-swallow tablets

A high-load matrix or more efficient polymer system could reduce tablet size. This opportunity has value for older patients and patients taking multiple chronic medicines. The formulation must preserve dose uniformity and extended-release performance.

Improved light-protective packaging

Nifedipine's photosensitivity creates a packaging opportunity. Aluminum-aluminum blisters, opaque high-barrier bottles, and optimized secondary packaging can reduce degradation risk. The commercial tradeoff is higher packaging cost, which must be balanced against stability, shipping, and complaint performance.

Manufacturing simplification

Direct compression or a reduced-step granulation process could lower cost if blend uniformity and release performance remain acceptable. Nifedipine's low dose relative to tablet mass can make content uniformity a central process concern. Continuous blending or improved ordered-mixture technology may create value where conventional blending produces segregation.

Excipient platform products

An excipient supplier could develop a ready-to-use matrix system for poorly soluble, extended-release cardiovascular drugs. The platform could target:

• Consistent release across polymer lots
• Lower sensitivity to compression force
• Improved robustness under alcohol challenge
• Reduced formulation development time
• Compatibility with direct compression
• Simplified scale-up

The strongest business model is likely a co-development or preferred-supplier agreement rather than a commodity excipient sale.

Lifecycle dosage forms

Potential line extensions include:

• Lower-dose tablets
• Smaller tablets
• Alternative blister packaging
• Adherence-oriented calendar packs
• Fixed-dose combinations with another antihypertensive
• Carefully developed sprinkle or dispersible formats

Each extension would require a new regulatory and clinical assessment. A modified-release formulation that changes administration instructions may require more than routine ANDA bridging.

How strong is the patent estate for AFEDITAB?

The likely patent position is weak at the molecule level and potentially meaningful only for narrowly claimed delivery technology. Patent strength should be scored across five dimensions:

Dimension	Likely assessment
Nifedipine composition-of-matter patent	Expired
Basic extended-release concept	Likely exposed to prior art
Specific matrix composition	Potentially enforceable if claims remain unexpired and product-specific
Manufacturing process	Moderate value if difficult to design around
Packaging and photoprotection	Usually limited unless tied to a demonstrated stability advantage

A new entrant should not assume that an old extended-release product is free of patent risk. It should also not assume that a broad polymer claim creates a durable barrier. The commercial value lies in claims that capture the actual tablet, survive validity review, and are difficult to avoid through a different polymer grade, coating, process, or release mechanism.

What generic launch risks exist?

The main launch risks are technical and commercial rather than chemical.

1. Dissolution mismatch against the reference product.
2. Failure under fed-state or alcohol-challenge testing.
3. Nifedipine photodegradation during stability studies.
4. Content-uniformity problems caused by segregation.
5. Tablet sticking or capping at commercial scale.
6. Excipient supplier changes that alter release performance.
7. Weak wholesale or pharmacy distribution.
8. Price erosion from multiple approved suppliers.
9. Substitution limits caused by therapeutic-equivalence coding.
10. Patent or settlement restrictions affecting launch timing.

What licensing deals could create value?

Potential licensing structures include:

• Excipient supplier licensing of a controlled-release matrix platform
• Contract development and manufacturing for a generic sponsor
• Regional rights for an improved packaging configuration
• Co-development of a smaller tablet or fixed-dose combination
• Technology transfer for continuous blending or matrix-tablet manufacture
• Supply agreements tied to minimum annual volumes

A license is more defensible when it includes validated process parameters, analytical methods, stability data, and scale-up support. A license based only on a general excipient list is unlikely to create durable pricing power.

Key Takeaways

• AFEDITAB CR is a mature nifedipine extended-release product whose value depends on formulation execution, not molecule exclusivity.
• The release-controlling polymer is the most important excipient from a performance and supply-chain perspective.
• Photoprotection, dissolution robustness, and tablet integrity are central technical priorities.
• The strongest commercial opportunities are dual sourcing, smaller tablets, improved packaging, manufacturing simplification, and platform excipient systems.
• Patent risk is likely concentrated in specific formulation, process, packaging, and method-of-use claims.
• Generic launch risk is driven primarily by comparative dissolution, stability, manufacturing scale-up, regulatory review, and price competition.
• A differentiated product requires a measurable technical advantage, not merely a different inactive-ingredient list.

FAQs About AFEDITAB Excipient Strategy

Can AFEDITAB CR be reformulated with a different polymer?

Yes, but the change must preserve the approved release profile and satisfy applicable regulatory requirements. Polymer substitution should be supported by material characterization, comparative dissolution, stability, and process-validation data.

Is nifedipine an attractive active ingredient for a new extended-release product?

It can be attractive for a low-cost generic or lifecycle product, but the market is mature and price competition is substantial. Commercial success requires manufacturing efficiency, reliable supply, or a clinically relevant dosage-form advantage.

Does an excipient change require a new FDA application?

The regulatory pathway depends on the nature and scale of the change. A post-approval change may be possible for an approved product, while a materially different dosage form or release mechanism may require a new application or supplemental filing.

Can AFEDITAB CR be made into a smaller tablet?

Potentially. Tablet-size reduction must maintain dose uniformity, mechanical strength, stability, and extended-release performance. A smaller tablet may require a higher-efficiency matrix system or a different manufacturing process.

Are biosimilar risks relevant to AFEDITAB?

No. AFEDITAB contains nifedipine, a small-molecule active ingredient. Competitive risk comes from generic drug products and therapeutic substitutes, not biosimilars.

References

1. U.S. Food and Drug Administration. (n.d.). AFEDITAB CR: Nifedipine extended-release tablets prescribing information. DailyMed.
2. Sweetman, S. C., ed. (2011). Martindale: The complete drug reference (37th ed.). Pharmaceutical Press.
3. U.S. Food and Drug Administration. (2019). Drug products or dosage forms that must not be crushed. FDA.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.